Results for tag: "Developmental And Epileptic Encephalopathies Drug"

Developmental and Epileptic Encephalopathies (DEE) are a group of rare neurological disorders that affect the development of the brain and can cause seizures. These disorders are caused by genetic mutations and can lead to intellectual disability, motor impairment, and behavioral problems. Treatment for DEE is limited and often involves a combination of medications, dietary changes, and lifestyle modifications. The DEE drug market is a rapidly growing segment of the Central Nervous System (CNS) drugs market. This market is driven by the increasing prevalence of DEE, the development of new treatments, and the increasing awareness of the condition. The market is expected to continue to grow in the coming years as more treatments become available and the demand for these treatments increases. Some of the major companies in the DEE drug market include AbbVie, Biogen, GlaxoSmithKline, Novartis, Pfizer, and Sanofi. These companies are actively developing new treatments for DEE and are investing heavily in research and development. Show Less Read more